Arca
Skip to content
Tools
Tools

LCK: Tyrosine-protein kinase Lck

Non-receptor tyrosine-protein kinase that plays an essential role in the selection and maturation of developing T-cells in the thymus and in the function of mature T-cells.

  • Drugs that act on it: 2
  • Approved: 1
  • In phases 1 to 3: 1
  • Sponsors: 2

Who is on it, and how far along

Every drug ChEMBL records acting on LCK, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Small molecule 2

Approved1

  • Pazopanib

Phase 30

    Phase 20

      Phase 11

      • JNJ-26483327

      The landscape

      Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials.
      PazopanibBoxed warningApprovedNovartis PharmaceuticalsSmall moleculeInhibitorTyrosine-protein kinase LCK inhibitor27
      JNJ-26483327Phase 1Johnson & JohnsonSmall moleculeInhibitorTyrosine-protein kinase LCK inhibitor0

      Open trials

      The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 8 in all, from ClinicalTrials.gov.
      First-Line Systemic Therapies in Advanced Renal Cell Carcinoma in SpainPazopanib—Active, not recruitingBristol-Myers SquibbOct 1, 2026
      A Phase I Study of Pazopanib in Combination With Trabectedin, Ipilimumab and Nivolumab (TraPIN) in Pediatric and Young Adult Patients With Recurrent Soft Tissue SarcomasPazopanibPhase 1RecruitingM.D. Anderson Cancer CenterMar 3, 2026
      A Study of IBR854 Combined With Pazopanib Versus Pazopanib in Advanced Renal Cell CarcinomaPazopanibPhase 2RecruitingImbioray (Hangzhou) Biomedicine Co., Ltd.Jul 25, 2025
      Study of Pazopanib Combined With Palbociclib for Refractory Solid Tumors With Co-amplified in the 11q13(FGF3/4/19/CCND1)PazopanibPhase 1 / Phase 2RecruitingTianjin Medical University Second HospitalMar 26, 2025
      Evaluation of the Efficacy and Safety of Pazopanib in Combination with TGI/CIV for Recurrent or Refractory Rhabdomyosarcoma in Children or AdolescentsPazopanibPhase 2RecruitingShandong Cancer Hospital and InstituteFeb 10, 2025
      Precision Medicine Trial Based on Molecular Matching Therapy for Patients With Standard Treatment ExhaustionPazopanibPhase 2RecruitingTianjin Medical University Second HospitalDec 18, 2024
      Systemic Therapy Alone or With Stereotactic Body Radiotherapy for Oligometastatic Kidney Cancer (STROKER Study)PazopanibPhase 3RecruitingSun Yat-sen UniversityDec 10, 2024
      A Study to Investigate Efficacy & Safety of Intratumoral INT230-6 Compared to US Standard of Care in Adults With Soft Tissue Sarcomas (INVINCIBLE-3)PazopanibPhase 3RecruitingIntensity Therapeutics, Inc.Feb 16, 2024

      Diseases most associated with it

      Open Targets association score, 0 to 1; all associations
      Severe combined immunodeficiency due to LCK deficiency
      0.76
      Cancer
      0.59
      Neoplasm
      0.50
      HIV infectious disease
      0.46
      Combined immunodeficiency
      0.46

      Genes and related targets

      Complexes and families that share a gene with this target
      Genes
      LCK
      Related
      SRC

      Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL258, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-18. Gene name, function (UniProt P06239, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets

      Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.